VXRT · Vaxart, Inc. · Executive Compensation
$0.32
+0.00 (+0.00%)
At close · Jul 8
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on management's current plan, the Company expects to have enough cash runway into the second quarter of 2027. If the Company is unable to raise additional capital in sufficient amounts or on acceptable terms, management's plans include further reducing or delaying operating expenses. These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from the date of the issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$126.27M
Shares
242.84M
Volume · Jul 8
11.57M
Avg daily vol (3M)
4.77M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Steven Lo | President and Chief Executive Officer | $2,085,768 |
| Andrei Floroiu | CEO | $1,931,356 |
| James Cummings | Chief Medical Officer | $1,212,535 |
| Sean Tucker | Chief Scientific Officer | $1,155,031 |
| Michael J. Finney | Former Interim Chief Executive Officer | $305,390 |
| Michael Finney | CEO | $305,390 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Andrei Floroiu | Former President and Chief Executive Officer | $1,866,844 |
| James Cummings | Chief Medical Officer | $1,174,934 |
| Sean Tucker | Chief Scientific Officer | $1,137,485 |
| Michael Finney | CEO | — |
| Steven Lo | President and Chief Executive Officer | — |
| Michael J. Finney | Former Interim Chief Executive Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Andrei Floroiu | Former President and Chief Executive Officer | $3,589,392 |
| James Cummings | Chief Medical Officer | $1,934,123 |
| Sean Tucker | Chief Scientific Officer | $1,888,689 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Andrei Floroiu | President and Chief Executive Officer | $2,410,175 |
| James Cummings | Chief Medical Officer | $2,379,993 |
| Sean Tucker | Senior Vice President and Chief Scientific Officer | $1,189,150 |
| Margaret A. Echerd | Senior Vice President and Principal Accounting Officer | $1,158,366 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Andrei Floroiu | President and Chief Executive Officer | $2,362,742 |
| Sean Tucker | Senior Vice President and Chief Scientific Officer | $1,224,008 |
| Margaret A. Echerd | Senior Vice President and Principal Accounting Officer | $1,129,695 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Wouter Latour | President and Chief Executive Officer | $747,711 |
| Sean Tucker | Senior Vice President and Chief Scientific Officer | $444,698 |
| Margaret A. Echerd | Senior Vice President and Principal Accounting Officer | $328,952 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Wouter Latour | President and Chief Executive Officer | $850,412 |
| Sean Tucker | Chief Scientific Officer | $378,008 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| James B. Breitmeyer, M.D., Ph.D. | member of the Board | Appointed | 2026-04-23 |
| Michael J. Finney, Ph.D. | Chair of the Board | Retired | 2025-09-02 |
| Jeroen Grasman | Principal Accounting Officer and Principal Financial Officer | Appointed | 2025-05-13 |
| Jeroen Grasman | Chief Financial Officer | Appointed | 2025-05-13 |
| Robert A. Yedid | the Board | Resigned | 2025-01-28 |
| Elaine J. Heron, Ph.D. | member of the Compensation Committee of the Board | Appointed | 2025-01-28 |
| Kevin Finney | member of the Board of Directors | Appointed | 2025-01-28 |
| Robert A. Yedid | Director | Appointed | 2024-06-13 |
| David Wheadon, M.D. | Director | Appointed | 2024-06-13 |
| Steven Lo | Director | Appointed | 2024-06-13 |
| Elaine J. Heron, Ph.D. | Director | Appointed | 2024-06-13 |
| W. Mark Watson, C.P.A. | Director | Appointed | 2024-06-13 |
| Michael J. Finney, Ph.D. | Director | Appointed | 2024-06-13 |
| Steven Lo | member of the Board | Appointed | 2024-03-06 |
| Michael J. Finney, Ph.D. | Interim President and Chief Executive Officer | Resigned | 2024-03-06 |
| Steven Lo | President | Appointed | 2024-03-06 |
| Steven Lo | Chief Executive Officer | Appointed | 2024-03-06 |
| David Wheadon | Lead Director | Appointed | 2024-01-16 |
| Michael J. Finney | Interim Chief Executive Officer | Appointed | 2024-01-16 |
| Andrei Floroiu | Member of the Board of Directors | Resigned | 2024-01-16 |
| Andrei Floroiu | President and Chief Executive Officer | Resigned | 2024-01-16 |
| Phillip E. Lee | Principal Accounting Officer | Appointed | 2022-12-19 |
| Phillip E. Lee | Chief Financial Officer | Appointed | 2022-12-19 |
| W. Mark Watson | member of the Compensation Committee | Appointed | 2022-08-25 |
| Michael J. Finney, Ph.D. | Chairperson of the Science and Technology Committee | Appointed | 2022-08-25 |